1. Diagnostic Kit Components & Reagents
Not in registry
Source Explicitly mentioned as primary cost for testing and product revenue.
Confidence: high
VCYT
T2S&P 1500Russell 2000Innovation (ARKK)Veracyte, Inc.
Loading chart…
OverviewVeracyte, Inc. is a diagnostics company offering genomic tests to guide cancer treatment and recurrence monitoring. Key products include Afirma for thyroid, Dec
Veracyte, Inc. is a diagnostics company offering genomic tests to guide cancer treatment and recurrence monitoring. Key products include Afirma for thyroid, Decipher for prostate and bladder, and Prosigna for breast cancer. They recently launched TrueMRD for bladder cancer recurrence and Prosigna LDT, which now has Medicare reimbursement. Veracyte sells to clinicians and cancer centers, aiming to personalize patient care.
Key Inputs And Sourcing
2. Direct Labor (Lab Personnel)
Not in registryaccess=api
Source Direct labor costs associated with performing tests.
Confidence: high
3. Royalties for Licensed Technologies
Not in registry
Source Included in cost of product revenue.
Confidence: high
4. Shipping & Delivery Services
Not in registry
Source Costs for transporting samples and product delivery.
Confidence: high
5. Laboratory Equipment & Infrastructure
Not in registry
Source Expenses associated with testing samples, including depreciation.
Confidence: medium
6. IT Expenses
Not in registry
Source Part of allocated overhead for testing.
Confidence: medium
7. Third-Party Contract Manufacturing Services
Not in registry
Source For diagnostic kit components, reagents, and labor costs after August 2025.
Confidence: medium
8. Packaging Materials
Not in registry
Source Mentioned as part of product revenue costs.
Confidence: low
9. Sales & Marketing Labor
Not in registryaccess=api
Source Expanding sales force to drive adoption of new products.
Confidence: medium
10. Research & Development Supplies
Not in registry
Source General laboratory supplies for R&D activities.
Confidence: low
Industry Publications
- JCO Precision Oncology (ascopubs.org) — Publishes original research and reviews advancing precision oncology, directly relevant to Veracyte's cancer diagnostics focus.
- Precision Oncology (MDPI) (mdpi.com) — An international, peer-reviewed, open-access journal covering all aspects of precision oncology.
- Today's Clinical Lab (Genomics Section) (todaysclinicallab.com) — Covers news and trends in clinical genomics and molecular diagnostics, crucial for monitoring the broader market and technological advancements.
- The Journal of Molecular Diagnostics (jmd.amjpathol.org) — Focuses on molecular diagnostics techniques, applications, and testing, directly aligning with Veracyte's core business.
- Precision Oncogenomics (tandfonline.com) — A fully Open Access journal publishing research on cancer genomics and its application in precision cancer treatment.
Economic Data Watch
1. FRED — National Health Expenditure Accounts (NHEA)
Matchedfred · access=api · map_only
Metric/field Total Health Expenditures
Cadence monthly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for Veracyte's tests.
Signal to watch Increasing trend indicates a growing market for healthcare services, including diagnostics.
Confidence: low
2. FRED — Personal Consumption Expenditures
Matchedfred · access=api · map_only
Metric/field Personal Consumption Expenditures: Health Care
Cadence monthly
Why it matters Reflects private sector spending on healthcare, which can influence patient access and commercial payer behavior for diagnostic tests.
Signal to watch Sustained growth suggests robust private demand for healthcare services.
Confidence: low
3. FRED — Gross Domestic Product (GDP)
Matchedfred · access=api · map_only
Metric/field Gross Domestic Product
Cadence monthly
Why it matters General economic health impacts consumer spending, insurance coverage, and overall healthcare budgets, indirectly affecting diagnostic test volumes.
Signal to watch Positive growth indicates a healthy economic environment supportive of healthcare spending.
Confidence: low
4. CMS — Clinical Laboratory Fee Schedule (CLFS)
Not in registry
Metric/field Preliminary and Final Payment Rates for Diagnostic Laboratory Tests
Cadence event_driven
Why it matters Directly impacts Medicare reimbursement rates for diagnostic tests, significantly affecting Veracyte's revenue and profitability, especially for tests like TrueMRD and Prosigna seeking coverage.
Signal to watch Favorable or stable rates are positive; significant declines are negative.
Confidence: high
5. FRED — Business Research and Development
Matchedfred · access=api · map_only
Metric/field Research and development in the pharmaceutical and medicine manufacturing industry
Cadence monthly
Why it matters Indicates investment trends in the broader life sciences and diagnostics sector, which can signal innovation, competition, and potential partnership opportunities.
Signal to watch Increasing R&D spending suggests a dynamic and growing industry.
Confidence: low
Free Alt Data Watch
1. ClinicalTrials.gov — Study Results Database
Not in registry
Metric/field Trial Status, Enrollment, and Primary Outcome Results for VCYT-sponsored studies
Cadence irregular
Why it matters Updates on clinical trials (e.g., OPTIMA, NIGHTINGALE, Decipher studies) are critical for new product launches, guideline inclusion, and expanding clinical utility, directly impacting future adoption and reimbursement.
Signal to watch Positive trial readouts, increased enrollment, and successful completion are positive indicators.
Confidence: high
2. SEC EDGAR — Company Filings
Matched (medium)tegus_company_filings_financial_research · access=file · map_only
Metric/field 8-K filings (material events), 10-Q/10-K (financial and operational updates)
Cadence event_driven
Why it matters Provides timely official updates on reimbursement discussions (e.g., MolDX for Prosigna, TrueMRD), product launches, partnerships, and financial performance.
Signal to watch Filings detailing favorable reimbursement decisions, new product milestones, or strong financial results are positive.
Confidence: high
3. Google Trends — Search Interest
Not in registry
Metric/field Search term volume for 'Prosigna', 'Decipher Prostate', 'Afirma', 'TrueMRD'
Cadence weekly
Why it matters Indicates public and physician interest and awareness in Veracyte's key diagnostic products, signaling potential market adoption and demand.
Signal to watch Increasing search volume for Veracyte's products suggests growing awareness and interest.
Confidence: medium
4. Reddit — r/oncology subreddit
Matchedquid_social_media_sentiment · access=file · map_only
Metric/field Post volume and sentiment related to 'Veracyte', 'Prosigna', 'Decipher', 'Afirma', 'MRD testing', 'liquid biopsy'
Cadence daily
Why it matters Provides insights into physician and patient discussions, real-world experiences, and perceptions of Veracyte's tests and related diagnostic technologies.
Signal to watch Increased positive sentiment and discussion volume around Veracyte's products are favorable.
Confidence: medium
5. USPTO PatentsView — Patent Grants and Applications
Matched (medium)quid_patent_innovation_intelligence · access=file · map_only
Metric/field New patent grants/applications by assignee 'Veracyte' related to genomic diagnostics, liquid biopsy, and specific cancer types
Cadence irregular
Why it matters Tracking patent activity indicates Veracyte's innovation pipeline and competitive positioning in key diagnostic areas, potentially signaling future product developments.
Signal to watch Consistent new patent grants and applications suggest ongoing innovation and strengthening intellectual property.
Confidence: high
Paid Alt Data Watch
1. IQVIA / Symphony Health — Medical Claims Data
Matchediqvia_medical_claims · access=file · map_only
Metric/field CPT code utilization for Veracyte's molecular diagnostic tests (e.g., specific codes for Prosigna, Decipher, Afirma, TrueMRD)
Cadence monthly
Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends across commercial and Medicare payers, directly reflecting adoption rates.
Signal to watch Increasing CPT code utilization for Veracyte's tests, especially new launches, indicates strong market adoption.
Confidence: high
2. Definitive Healthcare — PhysicianView / HospitalView
Matched (medium)definitive_healthcare_hospital_facility_data · access=file · map_only
Metric/field Physician ordering patterns and hospital purchasing data for molecular diagnostic tests in oncology
Cadence monthly
Why it matters Offers insights into physician adoption rates, prescribing behavior, and institutional uptake of Veracyte's tests, particularly for high-volume centers and new product integration.
Signal to watch Expansion in the number of ordering physicians and increasing test volumes per physician are positive indicators.
Confidence: high
3. Truveta / HealthVerity / PurpleLab — De-identified Patient Data / Linked Claims
Matchedhealthverity_ehr_clinical_data · access=file · map_only
Metric/field Real-world evidence of test utilization, patient demographics, and clinical outcomes associated with Veracyte's diagnostics
Cadence monthly
Why it matters Provides real-world evidence of test impact, supporting clinical utility arguments for payers and physicians, and identifying new market opportunities.
Signal to watch Growing real-world utilization and positive patient outcomes associated with Veracyte's tests are strong indicators.
Confidence: medium
4. YipitData — Medtech Product Tracking
Matchedyipitdata_hospital_purchasing_medtech_procurement · access=file · map_only
Metric/field Hospital and surgical center purchasing data for diagnostic tests and related equipment
Cadence monthly
Why it matters Tracks actual purchasing activity by healthcare institutions, providing a direct measure of demand and adoption for Veracyte's tests within the hospital and clinic setting.
Signal to watch Increased purchasing volume or new institutional accounts for Veracyte's tests are positive.
Confidence: high
5. Spherix Global Insights — Market Research Reports / Physician Panels
Matched (medium)spherix_global_insights_physician_surveys · access=file · map_only
Metric/field Physician sentiment, competitive landscape analysis, and adoption forecasts for molecular diagnostics in oncology (e.g., breast, prostate, bladder, thyroid cancer)
Cadence irregular
Why it matters Offers qualitative and quantitative insights into physician perceptions, competitive dynamics, and future adoption trends, informing commercial strategy and market potential.
Signal to watch Reports indicating strong physician preference, increasing market share, and positive outlook for Veracyte's products are favorable.
Confidence: medium
Search Keywords Brand Product
- Afirma Genomic Sequencing Classifier
- Decipher Prostate
- Decipher Bladder
- Prosigna Breast Cancer Assay
- TrueMRD
- Percepta Nasal Swab Test
- cancer diagnostics
- genomic testing
- molecular residual disease
- MRD monitoring
- liquid biopsy
- precision oncology
- thyroid cancer
- prostate cancer
- breast cancer
- bladder cancer
- recurrence monitoring
Search Keywords Event Phrases
- Veracyte earnings
- OPTIMA trial results
- ASCO conference
- ESMO conference
Search Keywords Policy Regulatory
- MolDX coverage
- NCCN guidelines
- Medicare reimbursement diagnostics
- What They Do (Plain English & Analogies)
- Veracyte is like a specialized detective agency for cancer. Instead of looking for clues at a crime scene, they analyze tiny bits of a patient's biology (like cells from a thyroid nodule or DNA from a tumor) to figure out if cancer is present, how aggressive it is, and the best way to treat it. They help doctors make smarter decisions, often allowing patients to avoid unnecessary surgeries or harsh chemotherapy, or ensuring they get the right treatment early. They do this for various cancers, including thyroid, prostate, breast, and bladder cancer, and are expanding into monitoring for cancer recurrence.
- Very Brief History
- Veracyte, Inc. was incorporated in 2006, initially known as Calderome, Inc., before changing its name to Veracyte, Inc. in March 2008. Since its inception, the company has focused on developing and commercializing genomic diagnostic tests to guide patient care across multiple cancer types. Over the years, it has expanded its portfolio through internal innovation and strategic acquisitions, such as C2i Genomics, to offer a comprehensive suite of tests from risk assessment through recurrence monitoring.
- "Street Stereotype"
- Veracyte is generally perceived as a leader in high-value oncology diagnostic sub-specialties, particularly in thyroid, prostate, and breast cancer. Investors and analysts see it as a company leveraging genomic and AI-driven technologies to provide precision diagnostics and early detection, with a strong focus on generating robust clinical evidence to support its tests and drive adoption. It's viewed as a growth company within the MedTech diagnostics space, expanding its portfolio into new areas like molecular residual disease (MRD) monitoring.
- Subsidiaries On Linked In*
- C2i Genomics — Acquired by Veracyte, still maintains a distinct LinkedIn page.; LinkedIn: c2i-genomics
- Customer Sectors & Example Clients
- Veracyte's customers are primarily in the healthcare sector, specifically within oncology, urology, radiation oncology, and endocrinology. Their clients include physicians (oncologists, urologists, radiation oncologists, endocrinologists), academic cancer centers, large integrated health systems, and regional oncology networks. Specific client names are not provided in the transcript.
- New Customers / Segments They'Re Targeting
- Veracyte is actively targeting several new customer segments and expanding within existing ones. They are expanding access to Prosigna in the U.S. for approximately 225,000 patients diagnosed with ER-positive, HER2-negative breast cancer each year, particularly premenopausal women and patients with higher nodal involvement. They are also entering the rapidly growing molecular residual disease (MRD) market with TrueMRD for recurrence monitoring in muscle-invasive bladder cancer (MIBC) patients. Additionally, they are investing in generating additional high-quality evidence to support the use of Decipher in low-risk prostate cancer patients considering active surveillance, aiming for broader adoption and guideline inclusion in this untapped market.
- Sales Geographies And Expansion Plans
- Veracyte currently operates and sells its diagnostic tests in the United States and internationally. The recent launches of Prosigna LDT and TrueMRD are primarily discussed in the context of the U.S. market, with efforts focused on U.S. reimbursement (MolDX) and adoption by U.S. institutions. The transcript does not explicitly detail plans to expand sales into new international geographies, but rather focuses on expanding access and adoption within existing markets.
- How Key Themes May Help/Hurt
- Veracyte may benefit from the 'Diagnostics & Early Detection' theme through: 1) **Accelerating technological advancements in genomics, AI, and multiomics:** Veracyte's genomic diagnostic tests, whole-genome TrueMRD platform, and integration of AI-driven technology (via C2i Genomics) align directly with this trend. 2) **Increasing global prevalence of chronic diseases, particularly cancer, and an aging population:** This creates a sustained demand for Veracyte's cancer diagnostic and monitoring tests. 3) **Favorable regulatory developments and legislative actions:** Expanded Medicare and commercial coverage, along with potential guideline inclusions for new assays, can enhance market access. Conversely, Veracyte may be hurt by: 1) **Persistent reimbursement pressures and evolving payer policies:** Ongoing discussions with MolDX for Prosigna coverage and the impact of prior period collections highlight direct financial challenges. 2) **Significant regulatory hurdles and lengthy approval processes:** The need for extensive evidence generation for new indications and guideline inclusion can delay market expansion. 3) **Intensifying competition:** The highly competitive diagnostics market could lead to pricing pressures and increased commercialization costs.
3 Main Long-Term Bull Details
- Robust Product Pipeline and Platform Extensibility: The recent launches of Prosigna LDT and the TrueMRD platform, particularly its whole-genome sequencing approach, demonstrate Veracyte's ability to innovate and expand its portfolio across multiple cancer types and the cancer care continuum, offering significant future growth opportunities beyond current indications. 2. Strong Clinical Evidence and Guideline Potential: Veracyte consistently generates high-quality, often Level 1A, clinical evidence for its tests (e.g., Prosigna with OPTIMA trial, Decipher in intermediate/high-risk prostate cancer), which is crucial for driving physician adoption, securing reimbursement, and achieving inclusion in clinical guidelines, thereby solidifying its market position. 3. Durable Core Franchises and Operational Efficiency: Established tests like Decipher Prostate and Afirma continue to deliver double-digit revenue and volume growth, supported by expanding customer bases, increasing utilization, and operational improvements (like Afirma's V2 transcriptome workflow reducing no-result rates), providing a strong financial foundation for future investments and growth.
3 Main Long-Term Bear Details
- Reimbursement and Coverage Challenges: Despite strong clinical evidence, securing and maintaining favorable reimbursement, particularly for new product launches like Prosigna LDT and TrueMRD with MolDX, remains a significant hurdle that can delay revenue recognition and impact profitability. 2. Reliance on Guideline Updates and Evidence Generation: The company's growth in certain segments, such as Decipher in low-risk prostate cancer, is heavily dependent on future clinical evidence readouts and subsequent inclusion in NCCN guidelines, introducing a degree of uncertainty and a time lag for market expansion. 3. Intense Competitive Landscape: Veracyte operates in a highly competitive diagnostics market with both established players and emerging technologies (e.g., AI-based testing, other MRD platforms). This competition could lead to pricing pressures, increased sales and marketing expenses, and challenges in maintaining market share.
- Competitors And Differentiation
- Key competitors include Exact Sciences (with Oncotype DX) in breast cancer diagnostics, and other companies in the broader diagnostics and early detection space like Natera (Signatera), Guardant Health (Guardant Reveal), and Tempus AI in MRD or comprehensive genomic profiling. Veracyte differentiates itself through: 1) **Prosigna:** Backed by Level 1A prospective evidence from the OPTIMA trial, providing unique clinical utility for premenopausal women and patients with higher nodal involvement. 2) **TrueMRD:** Utilizes a whole-genome sequencing approach for both landmark testing and longitudinal monitoring, offering a broader view of tumor biology. 3) **Decipher:** Supported by extensive high-quality evidence and strong guideline support across various prostate cancer risk groups. 4) **Afirma:** Maintains market leadership through continuous evidence generation, operational efficiencies, and strong physician adoption.
- Recent Performance & What The Market'S Focused On
- Veracyte delivered a strong second quarter in 2026, with total revenue of $150.3 million (up 15% year-over-year) and total volume of approximately 51,000 tests (up 13% year-over-year). Testing revenue grew 19% year-over-year, driven by Decipher (up 20%) and Afirma (up 18%). The company generated $45.8 million in cash from operations and reported a GAAP net income of $25.5 million. Adjusted EBITDA was $44 million, or 29.2% of revenue, exceeding their long-term target. The market is currently focused on the uptake and reimbursement of new launches (Prosigna LDT and TrueMRD), Decipher's performance (especially low-risk volumes and future evidence), sustained profitability and cash generation, and the development of their pipeline (TrueMRD expansion, NIGHTINGALE study).
- Revenue Segments And Estimated Mix
- Decipher (Prostate & Bladder Genomic Classifiers) — Mix: ~60%; Source: Q2 2026 transcript, estimated from volume and total testing revenue; Trend: 20% year-over-year revenue growth
- Afirma (Thyroid Genomic Sequencing Classifier) — Mix: ~37%; Source: Q2 2026 transcript, estimated from volume and total testing revenue; Trend: 18% year-over-year revenue growth
- Other Testing Revenue (Cytology services, Decipher Bladder) — Mix: ~3%; Source: Q2 2026 transcript, implied from total and testing revenue; Trend: Modestly below total testing revenue growth
- Product Brands
- Afirma Genomic Sequencing Classifier
- Decipher Prostate Genomic Classifiers
- Decipher Bladder Genomic Classifier
- Prosigna Breast Cancer Assay
- Prosigna LDT
- Percepta Nasal Swab Test
- TrueMRD
- Afirma GRID
Bull / Bear DetailsVeracyte maintains a strong bullish outlook (as of October 22, 2026) driven by the successful launches of Prosigna LDT and TrueMRD, significantly expanding its
Thesis
Veracyte maintains a strong bullish outlook (as of October 22, 2026) driven by the successful launches of Prosigna LDT and TrueMRD, significantly expanding its oncology diagnostics portfolio. Robust double-digit growth in core franchises (Decipher, Afirma) and industry-leading profitability underscore its operational strength. While Decipher's low-risk segment faces temporary guideline-related headwinds, a deep clinical pipeline and strategic investments position Veracyte for sustained long-term growth and market leadership in precision oncology.
Bull case
The recent launches of Prosigna LDT for breast cancer and TrueMRD for muscle-invasive bladder cancer recurrence monitoring significantly expand Veracyte's addressable market and growth opportunities. Prosigna, backed by Level 1A OPTIMA trial data, is seeing "tremendous enthusiasm" and is driving sales force expansion, while TrueMRD's whole-genome approach offers a differentiated entry into a rapidly growing market.
Veracyte's core franchises, Decipher Prostate and Afirma, continue to demonstrate strong performance with double-digit revenue growth (20% and 18% year-over-year, respectively, in Q2 2026). This growth is fueled by increased utilization, expanding physician bases, market share gains, and operational efficiencies like Afirma's improved no-result rate, contributing to industry-leading profitability and cash generation.
The company maintains a robust pipeline of clinical evidence and ongoing studies, particularly for Decipher in low-risk prostate cancer with readouts expected as early as 2027, aiming to expand guideline inclusion and market penetration. Additionally, continued evidence generation for Prosigna, Decipher Bladder, and the extensible TrueMRD platform supports long-term growth and strengthens Veracyte's competitive position across the cancer care continuum.
Bear case
Veracyte faces persistent reimbursement pressures and evolving payer policies, particularly for novel tests like Prosigna LDT and TrueMRD. While MolDX discussions for Prosigna are constructive, revenue guidance currently excludes contributions from these new tests, highlighting the potential for delayed coverage and market uptake challenges that could impact profitability and commercialization timelines.
The company experienced a slight reduction in its Decipher Prostate volume guidance for the year, primarily in the low-risk setting, due to a 2025 NCCN guideline change that removed active surveillance genomic testing. This indicates that guideline shifts can significantly impact market segments, and future growth in this area is contingent on new evidence and subsequent guideline re-inclusion, which is not guaranteed.
Despite strong overall financial performance, Veracyte's maintained Adjusted EBITDA guidance of 'greater than 26%' reflects significant planned investments across its deep pipeline and commercial expansion efforts. While necessary for future growth, these investments, coupled with potential gross margin headwinds from new product volumes without initial reimbursement, could temper near-term profitability expansion.
Bull / Bear Case
- Bear Case
- Veracyte faces persistent reimbursement pressures and evolving payer policies, particularly for novel tests like Prosigna LDT and TrueMRD. Revenue guidance currently excludes contributions from these new tests, highlighting potential for delayed coverage and market uptake challenges that could impact profitability and commercialization timelines. The company experienced a slight reduction in its Decipher Prostate volume guidance for the year, primarily in the low-risk setting, due to a 2025 NCCN guideline change, indicating that guideline shifts can significantly impact market segments. Despite strong overall financial performance, maintained Adjusted EBITDA guidance reflects significant planned investments across its deep pipeline and commercial expansion efforts, which, coupled with potential gross margin headwinds from new product volumes without initial reimbursement, could temper near-term profitability expansion.
- Bull Case
- Veracyte's recent launches of Prosigna LDT for breast cancer and TrueMRD for muscle-invasive bladder cancer recurrence monitoring significantly expand its addressable market and growth opportunities. Prosigna, backed by Level 1A OPTIMA trial data, is generating "tremendous enthusiasm" and driving sales force expansion, while TrueMRD's whole-genome approach offers a differentiated entry into a rapidly growing market. The company's core franchises, Decipher Prostate and Afirma, continue to demonstrate strong performance with double-digit revenue growth (20% and 18% year-over-year, respectively, in Q2 2026). This growth is fueled by increased utilization, expanding physician bases, market share gains, and operational efficiencies, contributing to industry-leading profitability and cash generation. A robust clinical evidence pipeline supports long-term growth and strengthens Veracyte's competitive position.
- More Compelling & Why
- Bull. Despite being considered 'Modestly Overvalued' by some intrinsic value models, Veracyte's Forward P/E of 22.9x is significantly below the industry average and cheaper than over 90% of its peers, especially considering its expected 21% annual earnings growth. The successful launch of two key growth drivers, Prosigna and TrueMRD, alongside sustained double-digit growth in core franchises and strong profitability, makes the bull case more compelling. A significant delay or unfavorable outcome in MolDX reimbursement for Prosigna, or a material deceleration in the growth of Decipher and Afirma beyond current expectations, would flip my view to Bear.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Publication of Prosigna OPTIMA Trial Results in Leading Peer-Reviewed Journal | Publication of the practice-changing OPTIMA trial results, which provide Level 1A evidence, is an important milestone for further validating Prosigna and supporting its potential inclusion in future clinical guidelines, driving broader physician adoption. | Announcement from Veracyte or the independent study group regarding the publication of the OPTIMA trial results in a leading peer-review journal. | Publication in a leading peer-reviewed journal = bullish signal. Significant delays in publication or rejection = bearish signal. | Company press releases, medical journal databases, updates from major oncology conferences (e.g., ASCO, ESMO). | [] | [] |
| Afirma Revenue and ASP Performance | Afirma continues to be a strong performer, driven by increased utilization, market share gains, and favorable reimbursement wins. Sustained ASP improvement and revenue growth are key contributors to overall company profitability. | Afirma's year-over-year revenue growth and average selling price (ASP) in Q3 2026 and Q4 2026. Management increased full-year revenue guidance to 12% to 14% year-over-year growth and expects ASP to be slightly higher than 2025. | Afirma revenue growth at or above 12% year-over-year and continued ASP improvement = bullish signal. Revenue growth below guidance or ASP decline = bearish signal. | Company earnings reports and conference calls for Q3 2026 (expected late October/early November 2026) and Q4 2026 (expected late January/early February 2027). | [] | [] |
| Prosigna LDT Medicare Reimbursement Decision (MolDX) | Securing Medicare reimbursement for the Prosigna LDT is critical for unlocking significant market access among Medicare beneficiaries and enabling revenue recognition for this newly launched product, which is currently excluded from revenue guidance. | Announcement of MolDX approval for the Prosigna LDT tech assessment and agreement on pricing. Management expects approval to be 'imminent' and pricing around the low end of $2,500. | Approval of the tech assessment and favorable pricing (at or above $2,500) = bullish signal. Delays in approval or lower than expected pricing = bearish signal. | Company press releases, SEC filings (10-Q/K), MolDX website. The company anticipates providing updates as discussions progress. | [] | [] |
| Decipher Prostate Volume Growth in Intermediate and High-Risk Settings | The intermediate and high-risk segments are durable growth drivers for Decipher Prostate, demonstrating strong underlying demand and offsetting adjustments in the low-risk category. Continued strong performance is crucial for meeting overall revenue guidance. | Decipher Prostate test volumes for Q3 2026 and Q4 2026. Management expects approximately 31,000 tests in Q3 and 33,000 in Q4. | Q3 volume at or above 31,000 tests and Q4 volume at or above 33,000 tests = bullish signal. Volumes significantly below these targets = bearish signal. | Company earnings reports and conference calls for Q3 2026 (expected late October/early November 2026) and Q4 2026 (expected late January/early February 2027). | [] | [] |
| TrueMRD Commercial Adoption and Evidence Generation Progress | TrueMRD represents Veracyte's entry into the rapidly growing molecular residual disease (MRD) market and is a potential long-term growth driver. Early commercial feedback and continued evidence generation are crucial for future expansion. | Updates on initial physician feedback, ordering activity, and progress in evidence generation for TrueMRD, particularly for MIBC and potential expansion to other tumor types. | Positive updates on adoption, increased ordering platform activity, and announcements of new evidence generation or pipeline expansion = bullish signal. Lack of significant progress or negative feedback = bearish signal. | Company earnings calls, investor presentations, and scientific conference presentations. | [] | [] |
Key Reported Metrics, Reratings Triggers & ResultsAfirma is an established market leader. Its consistent revenue growth, driven by increased utilization, market share gains, and operational efficiencies, contri
Upcoming print · 2026-11-04
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Afirma Revenue Growth | 18% | Afirma is an established market leader. Its consistent revenue growth, driven by increased utilization, market share gains, and operational efficiencies, contributes significantly to Veracyte's overall financial strength and profitability. Investors expect continued momentum. | Afirma revenue growth of 15% year-over-year or higher for Q3 2026, demonstrating sustained momentum above the company's full-year guidance range of 12-14% and closer to the prior quarter's strong performance. | Consistent Afirma growth above guidance reinforces its market leadership and operational efficiency. This signals strong demand and effective execution, contributing significantly to overall financial strength and cash generation, which is crucial for funding new product launches and validating the bullish thesis. | |
| Decipher Revenue Growth | 20% | Decipher is a core growth driver, and its continued strong performance, particularly in intermediate and high-risk prostate cancer, is crucial for Veracyte's sustained double-digit growth targets. Investors will watch for signs of offsetting low-risk segment headwinds. | Decipher Prostate test volumes of at least 31,500 for Q3 2026, translating to double-digit revenue growth of 18% year-over-year or more, indicating successful navigation of low-risk segment headwinds and robust performance in intermediate and high-risk settings. | Decipher is a core growth driver. Exceeding test volume targets and maintaining strong double-digit revenue growth, particularly in higher-risk segments, validates the company's strategy to overcome guideline challenges. This ensures sustained growth and reinforces investor confidence in Veracyte's oncology portfolio. | |
| Total Revenue | 15% | Total revenue growth indicates the overall financial health and market acceptance of Veracyte's diagnostic portfolio. It reflects the combined performance of core franchises and signals the initial impact of new product launches like Prosigna and TrueMRD, crucial for investor confidence. | Total revenue of at least $152 million for Q3 2026, significantly beating the consensus estimate of $147.16 million and representing year-over-year growth above 15%, signaling strong overall portfolio performance and early positive traction from new product launches. | Total revenue growth is the primary indicator of Veracyte's overall market acceptance and financial health. A substantial beat on consensus and strong growth signals successful execution across the portfolio, including promising early adoption of new products like Prosigna and TrueMRD, validating the bullish thesis. | |
Key QuestionsFollowing the secured MolDX reimbursement for Prosigna, will Veracyte successfully translate early physician enthusiasm and expanded sales force efforts into ac
Following the secured MolDX reimbursement for Prosigna, will Veracyte successfully translate early physician enthusiasm and expanded sales force efforts into accelerated commercial volume and revenue growth for the test?
- Question 2
Can Decipher Prostate sustain its strong revenue growth trajectory, particularly in intermediate and high-risk segments, offsetting the near-term volume reduction in the low-risk category due to NCCN guideline changes?
- Question 3
What is the initial commercial traction and adoption rate for TrueMRD in muscle-invasive bladder cancer, and what concrete progress will Veracyte demonstrate in expanding its MRD platform to additional tumor types or indications?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Successful Launch and Commercialization of New Products**: Management is highly focused on the recent launches of Prosigna LDT and TrueMRD, viewing them as key growth opportunities and significant milestones for the company. They are expanding the sales force for Prosigna ahead of schedule due to strong demand and are encouraged by initial feedback for TrueMRD. 2. **Continued Growth and Profitability of Core Franchises**: Veracyte aims to sustain double-digit growth in its established Decipher and Afirma franchises, driven by increased adoption, market share gains, and operational efficiencies. They are particularly focused on expanding Decipher's use in intermediate and high-risk prostate cancer, and Afirma's utilization and market share. 3. **Evidence Generation and Clinical Validation**: A significant focus is placed on generating high-quality clinical evidence to support and expand the utility of their tests. This includes ongoing studies for Decipher in low-risk prostate cancer, upcoming presentations for Decipher Prostate, and continued evidence generation for Afirma and Decipher Bladder, as well as the publication of OPTIMA trial results for Prosigna. | Call Takeaway & ToneThe overall takeaway of the call was positive, highlighting a milestone quarter for Veracyte with the successful launches of Prosigna LDT and TrueMRD, which are expected to be significant future growth drivers. The tone was confident and optimistic, reinforced by strong double-digit revenue growth in core franchises (Decipher and Afirma), industry-leading profitability, and robust cash generation. Management expressed strong conviction in their strategy, execution, and pipeline, despite a slight adjustment to Decipher's low-risk volume expectations due to guideline changes. The company is actively investing in commercial expansion and evidence generation to capitalize on new market opportunities and sustain long-term growth. | Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, Veracyte reported total revenue growth of 21% year-over-year. Testing revenue grew 26% year-over-year. Decipher revenue increased 30% year-over-year. Afirma revenue grew 21% year-over-year. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Decipher Low-Risk Volume and AI Competition**: Analysts questioned the lowered guidance for Decipher's low-risk segment and whether AI-based testing posed a threat. Management responded that the reduction was primarily in the low-risk category due to a prior NCCN guideline change affecting all tests in that segment, not a competitive threat from AI. They emphasized that molecular and AI are complementary, and physicians prefer more information. 2. **Prosigna Market Expansion, Adoption, and Reimbursement**: Analysts inquired about the addressable market for Prosigna, early adoption trends, and the MolDX reimbursement timeline. Management stated they believe the entire HER2-negative, ER-positive breast cancer population is addressable, not just node-positive patients. They expressed satisfaction with early adoption and engagement, including interest in broad adoption from major institutions. Regarding MolDX, they confirmed existing Medicare coverage for the FDA-approved product and a straightforward path for the LDT, with discussions progressing constructively and an imminent approval expected. 3. **Adjusted EBITDA Guidance and Investment Levels**: Analysts pressed on why the Adjusted EBITDA guidance remained at 'greater than 26%' despite strong Q1 and Q2 performance, and the level of investment being pulled forward for Prosigna. Management explained that the maintained guidance reflects significant planned investments across their deep pipeline (MRD, Decipher, Afirma, Prosigna) to drive future revenue growth. They also noted that prior period collections (PPCs) contributed to year-to-date outperformance and are not guided for, and that Prosigna volume in the latter half of the year, without initial reimbursement, would be a slight gross margin headwind. The Prosigna sales force expansion was noted as going from roughly 10 to 15 people. | Revenue SegmentsTotal revenue grew 15% year-over-year to $150.3 million. Testing revenue increased 19% year-over-year to $145.7 million. Decipher revenue grew 20% year-over-year. Afirma revenue grew 18% year-over-year. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketVeracyte launched Prosigna LDT and TrueMRD, which are catalyzing key growth opportunities and meaningfully expanding its portfolio. The company sees a significant opportunity to expand access to Prosigna in the U.S., where approximately 225,000 patients are diagnosed with ER-positive, HER2-negative breast cancer each year. Prosigna's OPTIMA trial results provide the only clinically validated evidence for premenopausal women and patients with higher nodal involvement, expanding its clinical utility. The TrueMRD platform is extensible well beyond bladder cancer, with the potential to support multiple tumor types and clinical applications over time. Low-risk disease represents an important growth opportunity for Decipher, with ongoing studies expected to expand its clinical foundation and support broader adoption and guideline inclusion over time. Veracyte aims for at least 80% penetration in the low-risk prostate cancer market, up from the current 20%. The company is also seeing strong ordering trends in intermediate and high-risk localized prostate cancer, as well as post-prostatectomy and biochemical recurrence, which remain large growth opportunities for Decipher. Decipher Bladder is showing a growing body of evidence across the bladder cancer continuum. Afirma continues to see increased utilization among existing physicians and expansion of its ordering physician base, leading to ongoing market share gains. | About CompetitionVeracyte does not perceive a specific threat from AI-based testing impacting Decipher's volumes, noting that the reduction in low-risk expectations affects all tests on the market similarly due to guideline changes. The company believes molecular and AI-based testing are complementary, measuring different aspects of biology, and that physicians prefer more information. Decipher Prostate is highlighted as the only gene expression test supported by high-quality evidence in its category. Afirma's competitive differentiation includes growing interest from independent investigators evaluating its clinical utility in real-world practice. For Prosigna, some physicians are contemplating a full switch from existing providers due to ease of dealing with one provider. | About The Broader IndustryThe Molecular Residual Disease (MRD) market is described as rapidly growing. Oncology research and testing are advancing, with capabilities like whole genome sequencing becoming increasingly important. The 2025 NCCN guideline update reinforced the need for additional high-quality evidence for genomic testing in low-risk patients considering active surveillance. The company believes molecular and AI approaches are complementary, measuring different biological aspects, and can potentially coexist rather than being a 'one or the other' model. | Where Things Are HeadedVeracyte is focused on continuing to expand its portfolio and is approaching the milestone of serving its one millionth patient. For Prosigna, publication in a leading peer-review journal is expected to further validate its evidence and support inclusion in future clinical guidelines. The company is focused on educating key opinion leaders and driving adoption in high-volume centers for Prosigna. For TrueMRD, Veracyte expects continued evidence generation, product enhancements, and portfolio expansion to strengthen its position in bladder cancer management. Decipher Prostate has a growing clinical data pipeline with initial readouts for low-risk and active surveillance populations expected as early as 2027, aiming to expand its clinical foundation and guideline inclusion. The company anticipates a steady drumbeat of conference presentations for Decipher in the second half of the year. Veracyte remains confident in Decipher's long-term growth opportunity, supported by customer base expansion, broader physician adoption, expanding evidence, and continued innovation. Afirma is expected to have more publications and scientific abstracts this year than in 2025, accelerating its momentum. The company expects to deliver durable double-digit growth for the foreseeable future and has raised its full-year total revenue guidance. Veracyte's capital deployment strategy prioritizes investment in the business, followed by M&A, and then returning capital to investors. The NIGHTINGALE study for the Percepta nasal swab test is considered a longer-term growth driver. | Updates On ThemeDiagnostics | Bullish-Leaning Quotes (Short)Q2 was a milestone quarter for Veracyte as we launched Prosigna LDT and TrueMRD, catalyzing two of our key growth opportunities and meaningfully expanding our portfolio. We delivered another quarter of double-digit growth and industry-leading profitability. We see a significant opportunity to expand access to Prosigna in the U.S. We are expanding our sales force ahead of our original plan to capture the demand we are seeing. We delivered another strong quarter with approximately 18,600 tests, representing 10% year-over-year volume growth and 18% revenue growth for Afirma. We are raising full-year total revenue guidance to $590 million-$596 million. | Bearish-Leaning Quotes (Short)We are taking our expectations for volume for the year down by approximately 1% or slightly more than 1,000 tests, primarily in the low-risk setting for Decipher Prostate. For every test, whether molecular or AI-based, for active surveillance, it was taken out of guidelines. We don't know if they're going to read out positively or not. We do not yet have Medicare reimbursement for Prosigna and are still early in the launch process, our revenue guidance excludes contribution from these tests. | HiringVeracyte is expanding its sales force ahead of its original plan to capture the demand seen for Prosigna, going from roughly a 10-person sales force exiting this year to a 15-person sales force as of this year. Sales and marketing expense increased reflecting hiring to support the existing portfolio and recent launches of Prosigna LDT and TrueMRD. The company is also heavily investing in its team to leverage internal and external resources for EHR integration to support its businesses. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| VCYT_5cea816f | later this year | 2026-10-23 | 2026-10-27 | Presentation of additional data at the ESMO 2026 Congress supporting Decipher Prostate's utility in high-risk disease and Decipher Bladder's growing body of evidence across the bladder cancer continuum. | These presentations will expand the clinical utility of Veracyte's Decipher tests, potentially driving continued adoption and long-term growth in prostate and bladder cancer management. | Ticker | 2026-07-30 | earnings_transcript |